We are redefining therapeutics by leveraging new protein building blocks to transform treatment for countless patients.
LEARN MORE
We’re solving for holy grail challenges in medicine. We search for unmet clinical needs that our platform can uniquely address. From autoimmune diseases to metabolic disorders, we’re only scratching the surface of possibilities to improve the lives of patients.
Daniel J. Mandell, PhD
Chief Executive Officer
GRObio is breaking barriers in protein engineering and therapeutic design. With our GRO platform we can deliver therapeutics with unprecedented capabilities in areas where others didn’t dare to go.
Christopher J. Gregg, PhD
Chief Science Officer
Leaps by Bayer is committed to advancing paradigm-shifting breakthroughs to permanently reverse autoimmune disease. Partnering with GRObio is an outstanding example of fulfilling this mandate. GRObio combines world-class science with pioneering approaches to protein engineering to create tomorrow’s therapies or even cures.
Jürgen Eckhardt, MD, MBA
Heads of Leaps by Bayer
The GRO Platform
The GRO platform expands the amino acid alphabet to overcome the limitations of protein therapeutics currently impeding the treatment of disease
We’re delivering on the long-awaited promise of protein therapeutics by solving the intrinsic limitations of proteins on potency, stability, and function. The GRO platform shortens development timelines and is the only system capable of seamlessly scaling production of NSAA (non-standard amino acid) proteins to meet clinical needs.
LEARN MORE
Our Pipeline
Today, we’re focused on our first two families of NSAA chemistries to drive our product pipeline
GRObio is advancing its first two families of NSAA chemistries to build its product pipeline. DuraLogic™ chemistries focus on therapeutic stability and dosing schedule, while ProGly™ chemistries provide biologics that reeducate the immune system to treat autoimmune disease, or to eliminate immunogenic side-effects of protein-based therapies.
LEARN MORE
Featured News
GRO Biosciences Announces $25M Series A Financing Led by Leaps by Bayer and Redmile Group
BOSTON, November 3, 2021 - GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics,…
Read More
